

Product Data Sheet

Product Name: Xanthorrhizol

Cat. No.: GC18519

Chemical Properties

Cas. No. 30199-26-9

Chemical Name 5-[(1R)-1,5-dimethyl-4-hexen-1-yl]-2-methyl-phenol

SMILES OC1=C(C)C=CC([C@H](C)CC/C=C(C)/C)=C1


Formula $C_{15}H_{22}O$ M.Wt 218.3

Solubility DMSO: Soluble, Ethanol: Soluble, Water: Slightly Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Xanthorrhizol, isolated from *Curcuma xanthorrhiza* Roxb, is a potential antibacterial agent.

Xanthorrhizol is a potential antibacterial agent from *Curcuma xanthorrhiza* against streptococcus mutants[1]. SEM analysis shows that, treatment of *Candida* species with MIC of Xanthorrhizol affects

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

the external morphology of these yeasts. Cells incubated in the presence of Xanthorrhizol demonstrate a greater tendency to clump compared with the control cultures. Xanthorrhizol treated *C. glabrata* cells shows minor abnormalities without a smooth or a slightly awkward surface. Xanthorrhizol-treated *Candida* cells exhibit deformation and protrusions on the cell surface, which is more clearly demonstrated with *C. guilliermondii* and *C. parapsilosis*. In general, *Candida* exposed to, Xanthorrhizol at concentrations 1 x MICs exhibits substantial ultrastructural abnormalities such as shape deformation, protrusion, rugged cells surface, and clumping[2].

Ear edema induced by the topical application of TPA is suppressed by pre-treatment with Xanthorrhizol in a dose-related manner ($P < 0.005$). Topical application of Xanthorrhizol alone does not induce ear edema in mice. All the mice treated with 7.5 nM TPA for 19 weeks after initiation by DMBA developed an average of 15.5 ± 2.3 skin tumors per mouse (tumor multiplicity). Pre-treatment with 2 and 6 μ M Xanthorrhizol reduces tumor multiplicity to 6.9 ± 1.1 ($P < 0.005$) and 4.0 ± 1.1 ($P < 0.005$), respectively, at 19 weeks. In addition, Xanthorrhizol at 2 and 6 μ M dose dependently lowers the percentage of tumor-bearing mice (tumor incidence) to 80 and 57%, respectively, at the termination of the experiments. Furthermore, the tumor multiplicity ($P < 0.05$) and incidence are reduced in the DMBA-initiated mice that are topically treated with Xanthorrhizol for 6 weeks after the induction of papillomas with hyperplasia, mild dysplasia and moderate dysplasia by topical TPA application for 6, 18 and 24 weeks, respectively. The increased ODC expression in mouse epidermis with acute inflammation and tumor promotion induced by TPA is inhibited by pre-treatment with Xanthorrhizol in a dose-dependent manner. The topical application of Xanthorrhizol after the induction of papillomas with hyperplasia and dysplasia also potently inhibited ODC expression[3].

References:

- [1]. Hwang JK, et al. izol: a potential antibacterial agent from *Curcuma xanthorrhiza* against *Streptococcus mutans*. *Planta Med.* 2000 Mar;66(2):196-7.
- [2]. YAYA RUKAYADI, et al. The Effects of Xanthorrhizol on the Morphology of *Candida* Cells. *Microbiology Indonesia*, 2007,1(2):98-100.
- [3]. Won Yoon Chung, et al. Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kB. *Carcinogenesis* vol.28 no.6 pp.1224–1231, 2007.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA